Scholarlink

Background <p>Ischemic complications following breast reconstruction remain a significant cause of morbidity. Hyperbaric oxygen therapy (HBOT) is increasingly used as an adjunctive modality to enhance perfusion and salvage threatened reconstructions, yet its therapeutic benefit in this setting remains unclear. This study aims to compare ischemic complications following reconstructive breast surgery in patients receiving HBOT versus non-HBOT therapies.</p> Methods <p>A systematic review and meta-analysis was conducted following PRISMA guidelines. PubMed, Embase, and CENTRAL were searched from inception to July 2025. Studies evaluating HBOT for postoperative ischemic complications following breast reconstruction were included. Comparative outcomes were synthesized using random-effects models, and single-arm outcomes were pooled using random-effects meta-analysis of proportions. Risk of bias was assessed with ROBINS-I, and the certainty of evidence was evaluated with GRADE.</p> Results <p>Of the 1721 records, seven studies met the inclusion criteria. HBOT did not significantly reduce hematoma (OR 2.92; 95% CI [0.47–18.06]; <i>p = </i>0.25), skin necrosis (OR 4.72; 95% CI [0.13–172.44]; <i>p = </i>0.40), or reoperation (OR 2.42; 95% CI [0.89–6.55]; <i>p = </i>0.08). Single-arm HBOT cohorts demonstrated pooled rates of seroma (16.1%), SSI (18.8%), return to the operating room for debridement (12.6%), and explantation (21.6%).</p> Conclusions <p>Across seven non-randomized studies, comparative evidence for HBOT versus standard care in ischemic complications after breast reconstruction is insufficient and inconclusive to determine whether HBOT reduces ischemic complications. HBOT may be considered selectively within protocolized multidisciplinary pathways, but stronger prospective comparative studies with standardized indications and outcome definitions are needed to clarify its role.</p> Level of Evidence III <p>This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors <a href="http://www.springer.com/00266">www.springer.com/00266</a>.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Hyperbaric Oxygen Therapy for Ischemic Complications and Salvage Following Breast Reconstruction: A Systematic Review and Meta-Analysis

  • 期刊论文

  • 发表日期：

    2026年6月17日

查看全文
  • Guilherme Franceschini Machado,
  • Jonathan Mokhtar,
  • Victoria Trasatti Romão,
  • Maria Fernanda Queiroz Ferreira,
  • João Pedro Serrão Perin,
  • Lucas Kreutz-Rodrigues,
  • Ana Clara Pimenta Servidoni,
  • Mila Meneguelli Miranda

摘要

Background

Ischemic complications following breast reconstruction remain a significant cause of morbidity. Hyperbaric oxygen therapy (HBOT) is increasingly used as an adjunctive modality to enhance perfusion and salvage threatened reconstructions, yet its therapeutic benefit in this setting remains unclear. This study aims to compare ischemic complications following reconstructive breast surgery in patients receiving HBOT versus non-HBOT therapies.

Methods

A systematic review and meta-analysis was conducted following PRISMA guidelines. PubMed, Embase, and CENTRAL were searched from inception to July 2025. Studies evaluating HBOT for postoperative ischemic complications following breast reconstruction were included. Comparative outcomes were synthesized using random-effects models, and single-arm outcomes were pooled using random-effects meta-analysis of proportions. Risk of bias was assessed with ROBINS-I, and the certainty of evidence was evaluated with GRADE.

Results

Of the 1721 records, seven studies met the inclusion criteria. HBOT did not significantly reduce hematoma (OR 2.92; 95% CI [0.47–18.06]; p = 0.25), skin necrosis (OR 4.72; 95% CI [0.13–172.44]; p = 0.40), or reoperation (OR 2.42; 95% CI [0.89–6.55]; p = 0.08). Single-arm HBOT cohorts demonstrated pooled rates of seroma (16.1%), SSI (18.8%), return to the operating room for debridement (12.6%), and explantation (21.6%).

Conclusions

Across seven non-randomized studies, comparative evidence for HBOT versus standard care in ischemic complications after breast reconstruction is insufficient and inconclusive to determine whether HBOT reduces ischemic complications. HBOT may be considered selectively within protocolized multidisciplinary pathways, but stronger prospective comparative studies with standardized indications and outcome definitions are needed to clarify its role.

Level of Evidence III

This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.